Engelsk titel: Anemia is a common problem in rheumatic disease
Läs online
Författare:
Turesson, Carl
Email: Carl.Turesson@med.lu.se
Språk: Swe
Antal referenser: 21
Dokumenttyp:
Översikt
UI-nummer: 15047017
Sammanfattning
Anemia is common in patients with rheumatoid arthritis (RA) and other chronic rheumatic disorders. The prevalence of anemia has been
estimated to be 10-15 % in recent surveys of patients with RA. This represents a decrease over time, most likely due to improved control of
disease activity with more extensive anti-rheumatic treatment. Iron deficiency due to gastro-intestinal bleeding and impaired iron utilization
in the context of chronic inflammation both contribute to anemia in patients with inflammatory arthritis. IL-6 induced hepcidin contributes to
retention of iron in the reticulo-endothelial system - an important mechanism in anemia of chronic disease. Treatment with TNF-inhibitors,
and, in particular, the anti-IL-6 receptor antibody tocilizumab, down-regulate hepcidin and improve hemoglobin levels in patients with RA.
Parenteral iron therapy is another important strategy in the treatment of anemia associated with rheumatic disease.